Study findings suggest that patients be screened for vitamin D deficiency before starting SGLT2 inhibitor therapy, or they should simply be prescribed vitamin D supplements.
Researchers propose the use of ratios of vitamin D metabolites that take into account individual differences in vitamin D binding proteins to improve prediction of secondary hyperparathyroidism risk.